(Q33810893)

29 July 2017

1 reference

title

Cytochrome P450 and therapeutic drug monitoring with respect to clozapine (English)

1 reference

29 July 2017

Buur-Rasmussen B

1

1 reference

PubMed ID

10625111

29 July 2017

Brøsen K

series ordinal

2

1 reference

PubMed ID

10625111

29 July 2017

language of work or name

English

0 references

publication date

1 December 1999

1 reference

European Neuropsychopharmacology

29 July 2017

1 reference

29 July 2017

9

1 reference

29 July 2017

453-459

1 reference

29 July 2017

6

1 reference

Clozapine--pharmacokinetic investigations and biochemical effects in man.

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Clinical significance of the sparteine/debrisoquine oxidation polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Fluvoxamine is a potent inhibitor of cytochrome P4501A2

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Isozyme specific drug oxidation: Genetic polymorphism and drug-drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Drug-Metabolizing Enzymes and Therapeutic Drug Monitoring in Psychiatry

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Relation of leukocyte counts during clozapine treatment to serum concentrations of clozapine and metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Dose-dependent pharmacokinetics of caffeine in humans: relevance as a test of quantitative liver function

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Clinical pharmacokinetics of clozapine in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Multiple-dose pharmacokinetics of clozapine in patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Single- vs multiple-dose pharmacokinetics of clozapine in psychiatric patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Determination of clozapine and desmethylclozapine in human plasma by high-performance liquid chromatography with ultraviolet detection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Potential impact of valproic acid therapy on clozapine disposition.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Solid-phase extraction and high-performance liquid chromatographic analysis of clozapine and norclozapine in human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Will routine therapeutic drug monitoring have a place in clozapine therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Seizure following addition of erythromycin to clozapine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Mechanisms of clozapine-induced agranulocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

EEG alterations and seizures during treatment with clozapine. A retrospective study of 283 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Clozapine plasma levels determined by high-performance liquid chromatography with ultraviolet detection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Plasma clozapine and desmethylclozapine levels in clozapine-induced agranulocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Rapid and sensitive determination of clozapine in human plasma using high-performance liquid chromatography and amperometric detection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Pharmacokinetics and pharmacodynamics of clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Comparison of levels of cytochromes P-450, CYP1A2, CYP2E1, and their related monooxygenase activities in human surgical liver samples

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Measurement of clozapine and norclozapine in plasma/serum by high performance liquid chromatography with ultraviolet detection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

On-line fully automated determination of clozapine and desmethylclozapine in human serum by solid-phase extraction on exchangeable cartridges and liquid chromatography using a methanol buffer mobile phase on unmodified silica

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Carbamazepine and plasma levels of clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Characterisation of theophylline metabolism in human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Expression of CYP1A1 and CYP1A2 genes in human liver

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Clozapine plasma levels and convulsions

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Nonlinear theophylline elimination

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Interaction between caffeine and clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Drug-induced aplastic anaemia and agranulocytosis. Incidence and mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

High-performance liquid chromatographic procedure for the determination of clozapine, haloperidol, droperidol and several benzodiazepines in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

Determination of clozapine and its metabolites in serum and urine by reversed phase HPLC.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900033-4

7 January 2021

10.1016/S0924-977X(99)00033-4

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10625111